Registry-listed formulations

Eplivanserin · chembl:CHEMBL257704

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

5 source entries across 5 studies. This list may not include all unresolved or historical entries.

  • eplivanserin (SR46349)Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • eplivanserin (SR46349)Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • eplivanserin (SR46349)Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • eplivanserin (SR46349)Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Eplivanserin (SR46349)Registry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
100%(7/7)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Phase 3
5
71%
Phase 2
1
14%
Phase 1
1
14%

Phase Distribution

1

Early Stage

1

Mid Stage

5

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
1(14.3%)
Phase 3Large-scale testing
5(71.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(7)

Detailed Status

Completed7

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (14.3%)
Phase 21 (14.3%)
Phase 35 (71.4%)

Trials by Status

completed7100%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_3

Efficacy and Safety of Eplivanserin 5mg/Day in Insomnia Characterized by Sleep Maintenance Difficulties

NCT00805350
completedphase_3

Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia

NCT00253968
completedphase_3

Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia Followed by Optional Extension up to 1 Year

NCT00253903
completedphase_3

Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia

NCT00308503
completedphase_2

Efficacy and Safety of SR46349B in Patients With Sleep Disorders in Fibromyalgia

NCT00313885
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT00805350Phase 3

Efficacy and Safety of Eplivanserin 5mg/Day in Insomnia Characterized by Sleep Maintenance Difficulties

Completed
NCT00253968Phase 3

Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia

Completed
NCT00253903Phase 3

Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia Followed by Optional Extension up to 1 Year

Completed
NCT00308503Phase 3

Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia

Completed
NCT00313885Phase 2

Efficacy and Safety of SR46349B in Patients With Sleep Disorders in Fibromyalgia

Completed
NCT00679900Phase 3

Comparison of Eplivanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties

Completed
NCT00913614Phase 1

Single Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluation of Eplivanserin in Children With Insomnia

Completed

All 7 trials loaded

Drug Details

Intervention Type
Drug
Molecule Type
Small molecule
Total Trials
7

External References

ChEMBL
CHEMBL257704

Names & Codes

Research Codes

SR-46349